Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics...
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company), a clinical-stage biopharmaceutical company focused on developing proprietary,...
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company), a clinical-stage biopharmaceutical company developing proprietary, innovative,...
VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201™s rapid onset of action and previously announced positive clinical resultsProgram is on track for Phase...
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company), a clinical-stage biopharmaceutical company developing proprietary, innovative...
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for...
Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE™s clinical development plans Program to feature KOL presentation covering unmet need and current treatment...
BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company), a clinical-stage biopharmaceutical company developing proprietary, innovative...
Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was...